Prior studies have revealed the potential dysregulation of SRC signaling in pancreatic ductal adenocarcinoma (PDAC) due to the alterations in CBL, where CBL acts as a pivotal molecule in modulating SRC and/or PI3K/AKT signaling. The gene discussed is SRC; the disease is pancreatic ductal adenocarcinoma.